Merck Other Non-Current Liabilities 2010-2024 | MRK
Merck other non-current liabilities from 2010 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Merck other non-current liabilities for the quarter ending June 30, 2024 were $7.329B, a 0.88% increase year-over-year.
- Merck other non-current liabilities for 2023 were $8.792B, a 5.63% increase from 2022.
- Merck other non-current liabilities for 2022 were $8.323B, a 11.78% decline from 2021.
- Merck other non-current liabilities for 2021 were $9.434B, a 23.34% decline from 2020.
Merck Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$8,792 |
| 2022 |
$8,323 |
| 2021 |
$9,434 |
| 2020 |
$12,306 |
| 2019 |
$11,970 |
| 2018 |
$12,041 |
| 2017 |
$11,117 |
| 2016 |
$8,514 |
| 2015 |
$7,345 |
| 2014 |
$7,813 |
| 2013 |
$8,136 |
| 2012 |
$10,327 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Merck Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-06-30 |
$7,329 |
| 2024-03-31 |
$8,262 |
| 2023-12-31 |
$8,792 |
| 2023-09-30 |
$7,343 |
| 2023-06-30 |
$7,265 |
| 2023-03-31 |
$8,244 |
| 2022-12-31 |
$8,323 |
| 2022-09-30 |
$8,660 |
| 2022-06-30 |
$8,951 |
| 2022-03-31 |
$9,742 |
| 2021-12-31 |
$9,434 |
| 2021-09-30 |
$9,469 |
| 2021-06-30 |
$9,872 |
| 2021-03-31 |
$12,241 |
| 2020-12-31 |
$12,306 |
| 2020-09-30 |
$12,027 |
| 2020-06-30 |
$12,446 |
| 2020-03-31 |
$11,550 |
| 2019-12-31 |
$11,970 |
| 2019-09-30 |
$11,085 |
| 2019-06-30 |
$11,283 |
| 2019-03-31 |
$11,585 |
| 2018-12-31 |
$12,041 |
| 2018-09-30 |
$11,887 |
| 2018-06-30 |
$12,028 |
| 2018-03-31 |
$11,473 |
| 2017-12-31 |
$11,117 |
| 2017-09-30 |
$7,713 |
| 2017-06-30 |
$8,068 |
| 2017-03-31 |
$8,324 |
| 2016-12-31 |
$8,514 |
| 2016-09-30 |
$8,793 |
| 2016-06-30 |
$8,378 |
| 2016-03-31 |
$7,374 |
| 2015-12-31 |
$7,345 |
| 2015-09-30 |
$7,887 |
| 2015-06-30 |
$7,913 |
| 2015-03-31 |
$7,677 |
| 2014-12-31 |
$7,813 |
| 2014-09-30 |
$6,968 |
| 2014-06-30 |
$8,175 |
| 2014-03-31 |
$7,956 |
| 2013-12-31 |
$8,136 |
| 2013-09-30 |
|
| 2013-06-30 |
|
| 2013-03-31 |
|
| 2012-12-31 |
$10,327 |
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$300.492B |
$60.115B |
|
Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda, Simponi , Januvia and Janumet, Bridion, Isentress, ProQuad, Gardasil, Pneumovax 23, RotaTeq and Belsomra. Merck made its biggest acquisition of Schering-Plough and sold off its Consumer Care business to Bayer. Other key acquisitions include Idenix Pharmaceuticals, Cubist Pharmaceuticals, Rigontec, ArQule and Acceleron Pharma. IMerck spun off products from its Women's Health unit, legacy drugs and biosimilar products into a new publicly traded company called Organon & Co.
|
